Canton Strategic Holdings (CNTN) Share-based Compensation (2021 - 2026)
Canton Strategic Holdings (CNTN) reported Share-based Compensation of $32.3 million for Q1 2026, up 14618.45% on a YoY basis from N/an in Q1 2025, and up 2586.64% quarter-over-quarter from -$1.3 million in Q4 2025.
Canton Strategic Holdings (CNTN) Share-based Compensation (2021 - 2026) Analysis & Trends
Canton Strategic Holdings has reported Share-based Compensation for 6 years, with the latest figure at $32.3 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 14618.45% year-over-year to $32.3 million; the trailing twelve-month figure through Mar 2026 stood at $31.7 million (up 3989.6% YoY), and the FY2025 full-year result was $8253.0, down 98.84% from the prior year.
- Share-based Compensation for Q1 2026 stood at $32.3 million, up from -$1.3 million in the prior quarter.
- The five-year high for Share-based Compensation was $32.3 million in Q1 2026, with the low at -$1.3 million in Q4 2025.
- Historically, Share-based Compensation has averaged $2.0 million across 5 years, with a median of $200000.0 in 2025.
- Annual changes were most pronounced in 2022 — Share-based Compensation slumped 7496.83% — and 2026, when it surged 14618.45%.
- Canton Strategic Holdings' Share-based Compensation stood at -$498694.0 in 2022, then soared by 216.68% to $581862.0 in 2023, then plunged by 63.72% to $211104.0 in 2024, then plunged by 714.54% to -$1.3 million in 2025, then jumped by 2586.64% to $32.3 million in 2026.
- The last three Share-based Compensation figures came in at $32.3 million (Q1 2026), -$1.3 million (Q4 2025), and $200000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Canton Strategic Holdings | 699.97 Mn | 658.44 Mn | - | 32.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.26 Mn |
| Mar 31, 2026 | 32.26 Mn |
| Dec 31, 2025 | -1.30 Mn |
| Dec 31, 2025 | -1.30 Mn |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 567,636.00 |
| Jun 30, 2025 | 567,636.00 |
| Mar 31, 2025 | 219,179.00 |
| Mar 31, 2025 | 219,179.00 |
| Dec 31, 2024 | 211,104.00 |
| Dec 31, 2024 | 211,104.00 |
| Sep 30, 2024 | 191,943.00 |
| Sep 30, 2024 | 191,943.00 |
| Jun 30, 2024 | 153,647.00 |
| Jun 30, 2024 | 153,647.00 |
| Mar 31, 2024 | 153,619.00 |
| Mar 31, 2024 | 153,619.00 |
| Dec 31, 2023 | 581,862.00 |
| Dec 31, 2023 | 581,862.00 |